May 14th 2024
The FDA has extended the review period for palopegteriparatide in treatment of hyperparathyroidism in adult patients by 3 months to August 14, 2024.
FDA Approves High-Concentrate, Citrate-Free Formulation of Biosimilar Adalimumab-adbm
The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.
What to Know about the Aprocitentan Approval for Resistant Hypertension, with Michael Weber, MD
March 25th 2024Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.